7317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hyperplasia

Sarafoglou, Kyriakie; Kim, Mimi; Lodish, Maya; Felner, Eric; Martinerie, Laetitia; Nokoff, Natalie; Clemente, Maria

View

7317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hyperplasia, 2024 (102.5Kb)

Author

Date

2024-10-05

Permanent link

https://hdl.handle.net/11351/12380

DOI

10.1210/jendso/bvae163.127

ISSN

2472-1972

Show full item record

Keywords

Corticotropin-releasing factor; Children; Classic congenital adrenal hyperplasia

Bibliographic citation

Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, et al. 317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hype. J Endocr Soc. 2024 Oct 5;8(Supplement_1):bvae163.127.